ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Murthy on Dual HER2 Blockade in HER2+ Breast Cancer

Rashmi K. Murthy, MD
Published: Monday, Aug 06, 2018



Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses dual HER2 blockade in HER2-positive breast cancer.

Patients who have early-stage HER2-positive breast cancer with a tumor size greater than 2 cm or node-positive disease are currently treated with neoadjuvant trastuzumab (Herceptin), pertuzumab (Perjeta), and chemotherapy. This regimen is based on 2 phase II trials, NeoSphere and TRYPHAENA, explains Murthy. Both studies showed an improvement in pathological complete response when dual HER2-targeted therapy was combined with taxane-based chemotherapy compared with single HER2-targeted therapy alone.

Additionally, the results of the APHINITY trial showed a benefit, though small, in disease-free survival in the adjuvant setting. Since December 2017, pertuzumab has been FDA approved in the adjuvant setting. This calls into question which patients benefit from receiving adjuvant trastuzumab and pertuzumab for the duration of 1 year, says Murthy. Biomarkers will help physicians answer this question, though none have been identified to date. Therefore, the decision rests on clinical judgement and patient comorbidities, says Murthy.


Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses dual HER2 blockade in HER2-positive breast cancer.

Patients who have early-stage HER2-positive breast cancer with a tumor size greater than 2 cm or node-positive disease are currently treated with neoadjuvant trastuzumab (Herceptin), pertuzumab (Perjeta), and chemotherapy. This regimen is based on 2 phase II trials, NeoSphere and TRYPHAENA, explains Murthy. Both studies showed an improvement in pathological complete response when dual HER2-targeted therapy was combined with taxane-based chemotherapy compared with single HER2-targeted therapy alone.

Additionally, the results of the APHINITY trial showed a benefit, though small, in disease-free survival in the adjuvant setting. Since December 2017, pertuzumab has been FDA approved in the adjuvant setting. This calls into question which patients benefit from receiving adjuvant trastuzumab and pertuzumab for the duration of 1 year, says Murthy. Biomarkers will help physicians answer this question, though none have been identified to date. Therefore, the decision rests on clinical judgement and patient comorbidities, says Murthy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x